FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?

FHLC offers a much lower expense ratio at 0.08% versus IYH's 0.38% and a slightly higher dividend yield of 1.40% versus 1.28%. IYH is more concentrated with 101 holdings compared with FHLC's 338, but both funds show similar risk, with five-year max drawdowns of about 17.7% to 17.9% and comparable beta near 0.6. The article is a comparative ETF analysis, so the likely market impact is limited, though it may influence healthcare sector allocation decisions.

Analysis

The real signal here is not that FHLC is cheaper; it is that the healthcare sector is still being priced as a quasi-defensive utility while its internal dispersion is widening. A broader, lower-fee basket like FHLC will increasingly capture the “pick-the-winners” effect from large-cap drug franchises plus the long tail of smaller med-tech and biotech, whereas IYH concentrates exposure into a few momentum leaders that can dominate returns in either direction. That matters if leadership narrows: IYH should outperform in a continued mega-cap pharma melt-up, but FHLC is the better vehicle if earnings breadth improves beyond the top three names.

Second-order, the lower drawdown similarity tells us portfolio construction is doing more work than headline concentration suggests. The market is implicitly treating healthcare as bond-like, but the sector still has idiosyncratic patent-cycle, pricing, and regulatory risk that can surface fast over a 3-6 month window. If drug-pricing rhetoric reaccelerates or one of the top weights stumbles, IYH’s heavier exposure will transmit that shock more directly; FHLC has a built-in shock absorber via broader weighting into secondary names.

The most interesting contrarian angle is that the “cheap ETF” trade may be too obvious. A 30 bps annual fee gap is trivial over a single catalyst window, so the better trade is not structural ownership but tactical relative-value around factor momentum in LLY/JNJ/ABBV. The article implicitly says the sector’s beta is low, but that understates how much alpha is now coming from stock selection within healthcare, not sector direction. In other words, the index wrapper matters less than the top holdings regime.

For the next 1-3 months, the key risk is a reversal in the mega-cap pharma tape; that would quickly erase IYH’s concentration premium and could compress both funds together. Over 12+ months, however, FHLC’s fee edge and broader capture should compound unless the market remains narrowly led by the same three names. The opportunity is to express a view on intra-sector leadership, not on healthcare beta itself.

Key Decisions for Investors

• Go long FHLC vs short IYH as a 3-6 month relative-value trade; thesis is that broader breadth and lower fees outperform if healthcare leadership broadens beyond LLY/JNJ/ABBV. Risk: IYH wins if mega-cap pharma keeps compounding at a faster pace than the rest of the sector.
• If seeking direct single-name exposure, prefer LLY over an ETF basket only on pullbacks; the top-weighted nature of both funds means LLY remains the marginal driver. Use a 1-2 month tactical entry after any 5-8% drawdown to avoid paying peak momentum.